A pathway to equity: Parkinson’s disease research study focuses on Black Americans

February 05, 2024
Dr. Vanessa Hinson evaluating ability of  a Black patient with Parkinson's disease to raise arms over head.
Dr. Vanessa Hinson (left) conducting an evaluation of Parkinson's disease patient Bernetha Wolfe (center), with the help of Kayleigh Clark (right). Photo by Sarah Pack.

The Michael J. Fox Foundation for Parkinson’s Research has chosen MUSC as one of four sites for the Black and African American Connections to Parkinson’s Disease (BLAAC PD) research study, a part of the Global Parkinson’s Genetics Program.

BLAAC PD will explore the genetic basis of Parkinson’s disease (PD) in the Black community by genotyping more than 150,000 people worldwide, setting the stage for the development of targeted treatments. According to the Parkinson’s Foundation, approximately 36,265 people with PD live in North Carolina and South Carolina.

Vanessa Hinson, M.D., Ph.D., director of the Parkinson’s Disease Foundation Center of Excellence at MUSC, will be the principal investigator for the MUSC site of the BLAAC PD study.

“When this opportunity came about for BLAAC PD to specifically look at and serve the Black and African American population, I thought that this was something our state should be doing, given that about 26.3% of South Carolinians are of that ancestry,” she said.

“If we could undo what goes wrong in a person's brain who has such a gene by delivering a targeted treatment to that particular gene mechanism, then we would potentially be able to halt the progression or reverse the Parkinson's issue directly.” --Dr. Vanessa Hinson

Studies have shown that PD can manifest in various ways due to differences in genetic mutations and subtypes. Specifically, people of African ancestry displayed a mutation that quadruples the risk of getting PD and is not seen in people of European ancestry. Delivering treatments that are specific to this subtype of PD could improve these patients’ outcomes.

 

Dr. Hinson evaluating a Black patient with Parkinson's disease 
Dr. Vanessa Hinson evaluating Parkinson's disease patient Bernetha Wolfe, with the assistance of Kayleigh Clark. Photo by Sarah Pack.

“If we could undo what goes wrong in a person's brain who has such a gene by delivering a targeted treatment to that particular gene mechanism, then we would potentially be able to halt the progression or reverse the Parkinson's issue directly,” she said.

The mutation that has already been identified in people of African ancestry is associated with a higher risk for cognitive impairment in PD. This novel finding creates a pathway for equity by laying the scientific foundation for targeted treatments that could improve cognition and memory for patients with PD in the Black community. BLAAC PD will also continue to look for other mutations implicated in PD in the Black population.

Hinson is proud that MUSC will be a site for BLAAC PD because she believes it will build community and create awareness of Parkinson’s disease research in Black and African American communities. To get the word out about the study, she will work with community champions as well as primary care providers statewide who are affiliated with MUSC Health’s Regional Health Network.

“It's about building trust and making sure people understand that MUSC is accessible,” explained Hinson.